Heterocyclic Compounds

Matches 201 - 250 out of 53,955	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/039829A1	INHIBITORS OF KIF18A AND USES THEREOF Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
WO/2024/032774A1	COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITOR Provided are a compound as a voltage-gated sodium channel inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The compound has the structural characteristics of formula (I).
WO/2024/034593A1	HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN Provided is a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer.　The present inventors examined compounds useful as an active ingredient of a pharmaceutical compos...
WO/2024/036218A1	IDH MUTATIONS AS BIOMARKERS FOR ZOTIRACICLIB THERAPY Provided is the use of isocitrate dehydrogenase (IDH1 and IDH2) mutations for selecting and treating cancer patients for zotiraciclib (TG02) therapy, for example, in treating cancers such as glioma, medulloblastoma, chondrosarcoma, chola...
WO/2024/036112A1	AMIDE PRODRUGS AND USES THEREOF Described herein are amide prodrugs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating a CNS disease or disorder.
WO/2024/034657A1	PHARMACEUTICAL COMPOSITION COMPRISING HETEROCYCLIC COMPOUND The present invention addresses the problem of providing a pharmaceutical composition for cancer treatment of colorectal cancer and/or lung cancer.　The present inventors have studied compounds useful as an active ingredient for a pharm...
WO/2024/036270A1	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/035626A1	HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to ...
WO/2024/034652A1	TERTIARY AMIDE DERIVATIVE SUBSTITUTED BY QUATERNARY CARBON The present disclosure provides: a tertiary amide derivative substituted by quaternary carbon that is useful as a medicine and a pharmaceutically acceptable salt of the tertiary amide derivative; a pharmaceutical composition comprising t...
WO/2024/035771A2	ULK3 INHIBITORS AND USES THEREOF The present disclosure provides compounds of Formula (I), Formula (II) and Formula (III) which are useful as inhibitors of ULK3 and methods of using the same to treat cancers, such as ULK-associated cancers, for example multiple myeloma ...
WO/2024/032661A1	KIF18A INHIBITOR AND USE THEREOF The present invention relates to the technical field of medicine, in particular to a KIF18A inhibitor compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer thereof, a pharmaceutical composition and prep...
WO/2024/032529A1	PROTEIN DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...
WO/2024/033353A1	COMPOUND, ORGANIC SEMICONDUCTING MATERIAL COMPRISING THE SAME, ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME AND DISPLAY DEVICE COMPRISING THE SAME The present invention relates to a compound, an organic semiconducting material comprising the same, an organic electronic device comprising the same and a display device comprising the same.
WO/2024/035950A1	INHIBITORS OF KIF18A AND USES THEREOF Provided are compounds of the Formula (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
WO/2024/032600A1	HETEROCYCLIC DERIVATIVE, AND COMPOSITION THEREOF AND PHARMACEUTICAL USE THEREOF Disclosed are a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, and a use thereof in...
WO/2024/035627A1	HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
WO/2024/032689A1	COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF The present disclosure relates to a compound of formula (I) or a salt thereof, an enantiomer thereof, a stereoisomer thereof, a solvate thereof, or a polymorph thereof, and use thereof. The present disclosure further relates to a pharmac...
WO/2024/033293A1	DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
WO/2024/032751A1	CRYSTAL FORM OF SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND METHOD FOR PREPARING SAME The present disclosure relates to a crystal form of a substituted 2-hydro-pyrazole derivative (I) and a method for preparing same, and further comprises use of the crystal form in preparing drugs for treating breast cancer and other canc...
WO/2024/032584A1	PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF The present invention relates to a protein tyrosine kinase inhibitor for treating protein tyrosine kinase-mediated proliferative diseases or symptoms, such as ocular diseases and malignant tumors accompanied by pathological neoangiogenes...
WO/2024/035194A1	NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME The present invention relates to a novel heteroaryl-substituted derivative and a composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases comprising same. The heteroaryl-substituted derivative ...
WO/2024/036100A1	SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, Z, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (...
WO/2024/033322A1	METAL COMPLEX, SEMICONDUCTOR LAYER COMPRISING A METAL COMPLEX AND ORGANIC ELECTRONIC DEVICE The present invention relates to a metal complex, a semiconductor layer comprising the metal complex and an organic electronic device comprising at least one metal complex thereof.
WO/2024/032410A1	COMPOSITION OF PIPERAZINE COMPOUND AND PD-1 INHIBITOR OR PD-L1 INHIBITOR AND USE THEREOF IN TREATING TUMORS The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.
WO/2024/034591A1	HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN To provide a compound useful as an active ingredient of a pharmaceutical composition for treating cancer, in particular, pancreatic cancer.　The present inventors examined compounds useful as an active ingredient of a pharmaceutical com...
WO/2024/032782A1	VACCINE ADJUVANTS AND USES THEREOF Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...
WO/2024/035925A2	N-CYCLOPROPYL-1-(4-(4-(FLUORO-18F)PHENYL)PYRIMIDIN-5-YL)-N-METHYLPIPERIDINE-4-CA RBOXAMIDE AND USES IN PET IMAGING Disclosed herein is a PET tracer compound N-cyclopropyl-1-(4-(4-(fluoro-18F)phenyl) pyrimidin-5-yl)-N-methyl piperidine-4-carboxamide or salt thereof, and uses as an imaging agent. In certain embodiments, this disclosure relates to precu...
WO/2024/027457A1	COMPOUND HAVING EV71 AND/OR CVA16 VIRUS INHIBITORY ACTIVITY AND APPLICATION THEREOF A compound which has EV71 and/or CVA16 virus inhibitory activity and an application thereof, belonging to the field of antiviral drugs. The compound has the structure of formula (I), has good EV71 and/or CVA16 virus replication inhibitor...
WO/2024/029489A1	KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT.　The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...
WO/2024/028782A1	NLRP3 INFLAMMASOME INHIBITORS The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relat...
WO/2024/031089A1	SARS-COV2 MAIN PROTEASE INHIBITORS The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
WO/2024/027795A1	ANTIBODY-DRUG CONJUGATE CONTAINING MYC PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF An antibody-drug conjugate containing an Myc protein degradation agent bioactive compound, a preparation method therefor, and use thereof in preventing and/or treating diseases related to abnormal cell activity, including but not limited...
WO/2024/027703A1	PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a PRMT5 inhibitor, and a preparation method therefor and a use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a use thereof in ...
WO/2024/027712A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a nitrogen-containing heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a compound as represented by formula (II). The compound has a goo...
WO/2024/027694A1	PROTEIN DEGRADATION AGENT The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...
WO/2024/028795A1	HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon l...
WO/2024/028363A1	HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
WO/2024/028808A1	AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
WO/2024/028364A1	ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND USES THEREOF The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
WO/2024/028169A1	NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...
WO/2023/129564A9	DEGRADERS OF GRK2 AND USES THEREOF Provided herein are compounds (e.g., compounds of Formulae (I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs thereof, pharma...
WO/2024/028650A1	PYRIDINIUM LIGHT EMITTING MOLECULES The present invention relates to light emitting pyridinium salts and synthesis thereof. The synthesis encompases the formation of the pyridine luminophores, their alkylation, an optional ion exchange sequence and purification. The presen...
WO/2024/029583A1	NOVEL PYRAZOLE DERIVATIVE AND USE OF SAME The present invention relates to: a compound represented by formula (I) (wherein Ar1 and Ar2 may be the same as or different from each other, and each represent a substituted or unsubstituted aromatic group; L1 represents a direct bond o...
WO/2024/027825A1	CDK INHIBITOR AND POLYMORPH OF PHOSPHATE THEREOF The present application provides a polymorph of a compound of formula (A), i.e., N-(1-((4-((3S,5S)-3,5-dimethylpiperazine-1-yl)phenyl)sulfony l)piperidin-4-yl)-4-((S)-tetrahydrofuran-3-yl)oxy)-5(trifluo romethyl)pyrimidine-2-amine, and a...
WO/2024/028365A1	SUBSTITUTED PYRIDONE GPR84 ANTAGONISTS AND USES THEREOF The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
WO/2024/027800A1	5-HT2A RECEPTOR INVERSE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...
WO/2024/029613A1	HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer.　The present inventors carried out investigations with regard to compounds useful as an active ingredient in a pharmac...
WO/2024/028458A2	MUSCARINIC RECEPTOR AGONISTS This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts th...
WO/2024/030651A1	GPX4 INHIBITORS AND USE THEREOF The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
WO/2024/026540A1	INHIBITORS AND USES THEREFOR Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention r...

Matches 201 - 250 out of 53,955	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >